Biomarker-driven Intermittent Docetaxel in Metastatic Castration-resistant Prostate Cancer

NCT04918810 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
6
Enrollment
OTHER
Sponsor class

Stopped Recruitment lower than expected. The proportion of patients with mGSTPi undetectable prior to chemo. was significantly higher than anticipated. Decision made to close due to insufficient patient numbers to able to obtain meaningful data collection.

Conditions

Interventions

Sponsor

Australian and New Zealand Urogenital and Prostate Cancer Trials Group

Collaborators